Coherus Oncology (CHRS) Research & Development (2013 - 2026)
Coherus Oncology (CHRS) posted Research & Development of $21.5 million for Q1 2026, down 30.45% sequentially from $31.0 million in Q4 2025, and down 11.55% YoY from $24.4 million in Q1 2025.
Coherus Oncology (CHRS) Research & Development (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Research & Development for 14 years, with the latest figure at $21.5 million in Q1 2026.
- Quarterly Research & Development fell 11.55% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.1 million (up 20.86% YoY) and the FY2025 annual result came in at $108.9 million, up 18.57% from the prior year.
- Research & Development declined to $21.5 million in Q1 2026 per CHRS's latest filing, from $31.0 million in the prior quarter.
- Over five years, Research & Development peaked at $82.9 million in Q1 2022 and troughed at $20.6 million in Q2 2024.
- A 5-year average of $31.2 million and a median of $26.4 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 621.02% in 2022, then tumbled 58.81% in 2023.
- Over 5 years, Research & Development stood at $29.0 million in 2022, then slipped by 9.14% to $26.4 million in 2023, then dropped by 21.27% to $20.8 million in 2024, then jumped by 49.21% to $31.0 million in 2025, then sank by 30.45% to $21.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $21.5 million, $31.0 million, and $27.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 21.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.44 Mn |
| Mar 31, 2026 | 21.54 Mn |
| Dec 31, 2025 | 30.97 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Jun 30, 2025 | 26.31 Mn |
| Mar 31, 2025 | 24.36 Mn |
| Dec 31, 2024 | 20.76 Mn |
| Sep 30, 2024 | 22.05 Mn |
| Jun 30, 2024 | 20.60 Mn |
| Mar 31, 2024 | 28.42 Mn |
| Dec 31, 2023 | 26.37 Mn |
| Sep 30, 2023 | 25.65 Mn |
| Jun 30, 2023 | 23.27 Mn |
| Mar 31, 2023 | 34.15 Mn |
| Dec 31, 2022 | 29.02 Mn |
| Sep 30, 2022 | 45.81 Mn |
| Jun 30, 2022 | 41.61 Mn |
| Mar 31, 2022 | 82.92 Mn |
| Dec 31, 2021 | 50.76 Mn |
| Sep 30, 2021 | 54.09 Mn |